Filing Analysis
Grace Therapeutics, Inc. filed an 8-K to disclose the update of its corporate presentation. The updated presentation, dated June 17, 2026, was attached as Exhibit 99.1.
📋 Key Facts
- The filing date is June 18, 2026.
- The company updated its corporate presentation as of June 17, 2026.
- The presentation is filed under Item 8.01 (Other Events).
Grace Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its financial results for the fiscal year ended March 31, 2026.
📋 Key Facts
- The filing date is June 18, 2026.
- The company reported financial results for the fiscal year ending March 31, 2026.
- The results were disseminated via a press release (Exhibit 99.1).
Grace Therapeutics announced the departure of Carrie D’Andrea as Vice President of Clinical Operations effective June 5, 2026. To ensure continuity, the company entered into a twelve-month consulting agreement with Ms. D’Andrea.
🚩 Red Flags
- Departure of a key executive overseeing Clinical Operations in a therapeutics company can signal internal instability or delays in clinical trial execution.
📋 Key Facts
- Carrie D’Andrea ceased serving as VP of Clinical Operations effective June 5, 2026.
- A twelve-month Consulting Agreement was signed on June 5, 2026, with a fee of $250 per hour.
- Stock option vesting will continue as long as Ms. D’Andrea provides services under the Consulting Agreement.
- Ms. D’Andrea will have 90 days post-consulting termination to exercise vested options.
- Severance benefits are contingent upon a release of claims and adherence to non-competition/non-solicitation covenants.
Grace Therapeutics, Inc. filed an 8-K to announce an update to its corporate presentation on April 27, 2026. The updated presentation was included as an exhibit to the filing for public disclosure.
📋 Key Facts
- The filing was made on April 27, 2026, under Item 8.01 (Other Events).
- An updated corporate presentation dated April 27, 2026, was attached as Exhibit 99.1.
- The report was signed by Chief Executive Officer Prashant Kohli.
Grace Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for GTx-104. The drug was intended for the treatment of patients with aneurysmal subarachnoid hemorrhage, and the CRL indicates the application will not be approved in its current form.
🚩 Red Flags
- Regulatory rejection (CRL) of a lead drug candidate's NDA.
- Significant uncertainty regarding the timeline and cost for potential re-submission.
- Potential requirement for additional clinical trials or data to address FDA concerns.
📋 Key Facts
- The FDA issued the Complete Response Letter on April 23, 2026.
- The NDA was for GTx-104, a candidate for aneurysmal subarachnoid hemorrhage.
- A CRL means the FDA has completed its review but cannot approve the application as submitted.
- The company issued a press release (Exhibit 99.1) regarding the regulatory decision.